The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) awarded a single-award $21 million indefinite delivery contract to Altasciences Clinical Kansas Inc., a contract research organization, to conduct pharmacokinetic and pharmacodynamic trials for medication development in substance use disorders.
Under this contract, NIDA issued a $1,838,615 firm fixed price delivery order to Altasciences to perform Phase 1 cocaine drug interaction trials from September 2023 through March 2025 in Overland Park, Kansas. The purpose of this contract is to provide clinical pharmacology research services to support NIDA's mission of advancing treatments for substance use disorders. No set-asides were used for this award.
Generated 5/22/24, 9:17 AM